Boulder, Colorado - August 24, 2018 – Bolder BioTechnology is pleased to announce that Dr. Sanchita P. Ghosh of the Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences, Bethesda, MD, was selected to give an oral presentation on preclinical studies of BBT-059, Bolder BioTechnology’s long-acting interleukin-11 analog, at the Military Health…Read more
Recent Posts by admbbt
Boulder, Colorado – April 27, 2018- Bolder BioTechnology, Inc. announced today that it has completed a Phase 1 clinical trial of BBT-015, a proprietary long-acting granulocyte colony-stimulating factor (G-CSF) analog, in healthy human volunteers. BBT-015 is being developed as a treatment for chemotherapy-related neutropenia in cancer patients and for Acute Radiation Syndrome. Demonstration that the…Read more
BOULDER, Colo., Aug. 2, 2017 /PRNewswire/ -- Bolder BioTechnology, Inc. announced today that it has commenced dosing of patients in a Phase 1 clinical trial of its proprietary long-acting granulocyte colony-stimulating factor (G-CSF) analog, BBT-015. The trial is designed to study the pharmacokinetics, pharmacodynamics, safety and tolerability of single subcutaneous doses of BBT-015 in healthy human subjects. BBT-015 is…Read more
9 News in Denver, Colorado aired a series of reports highlighting recent progress in the fight against Alzheimer’s Disease. One of the reports focused on studies led by Huntington Potter, Ph.D., Professor of Neurology and Director of Alzheimer’s Disease Research in the Department of Neurology and the Linda Crnic Center for Down Syndrome at the…Read more
Recent Comments by admbbt
No comments by admbbt yet.